Partners in Innovation
Guerbet is actively involved in many partnerships with first-rate academic research centers, but also with companies with which potential synergies can be envisaged.
In the MRI field Guerbet is a major player in the Franco-German Iseult project. Run in conjunction with the French Atomic Energy and Alternative Energies Commission’s NeuroSpin center, the University of Freiburg and the Siemens Medical Systems and Bruker companies and supported by Oseo Innovation, the Iseult project, initiated in 2006, aims to develop new contrast agents for imaging brain disease using high magnetic-field MRI.
Guerbet is participating in the IMAkinib strategic industrial innovation project (managed jointly with the OncoDesign and Ariana Pharmaceuticals companies), the purpose of which is to discover radiotracers enabling anti-tumor treatments to be monitored.
- The Gallimed project (which includes the Cyceron and Nordion imaging platforms) aims at developing a new radiotracer for positron-emission computed tomography, a nuclear medicine technique which potentially improves metastastic extension monitoring and the detection of certain primary cancers for which currently-available radiotracers are insufficient. Guerbet is participating in this project, which has received the Eureka label.
- Guerbet is piloting the IMOVA project, the aim of which is imaging (by nuclear medicine and MRI) of atherothrombosis, a very common arterial disease which causes ischemic, cardiac, cerebral or peripheral hemorrhage lesions.
- Guerbet is participating in the European NAD research project into nanoparticles for the diagnosis and treatment of Alzheimer’s disease and also the 7th FPRTD, a program aimed at coordinating and financing research in the European Union.
- Guerbet is also involved in the SpineInject project alongside the Graftys company which is developing phosphocalcic cements which can be used as an alternative to bone grafts of biological origin in the spinal column. The aim of the project is to create a cement containing a radio-opaque contrast agent to monitor the correct implantation of the cement and its bioabsorption.